预约演示

The AKT is over: Roche finally dumps phase 3 prostate cancer prospect

2023-02-02

临床3期临床2期临床1期临床结果临床失败

Roche also pulled a phase 1 trial of efmarodocokin alfa in aGVHD from its pipeline.

Roche’s long-stuttering attempt to brefmarodocokin alfag caaGVHDte ipatasertib to market has run out of steam. After multiple clinical setbacks, the Swiss pharma giant has dropped (PDF) a phase 3 prostate cancer trial—and sent its acute graft-versus-host disease (aGVHD) prospect packing at the same time.

Rochesertib is a small molecule inhibitor of cancerart of a signaliipatasertibimplicated in the progression of prostate cancer and other tumor types. The candidate, which emerged from a collaboratprostate canceray BioPharma and Rocacute graft-versus-host disease (aGVHD)e 3 trials in breast and prostate cancer but delivered underwhelming data.

Ipatasertibted failures in two breast cancer AKTications in 2020 and 2021. Things went slightly better in a proprostate cancerial that detumored topline data in 2020, with the study hitting its co-primary endArray BioPharmaet ofRocheentGenentechling in the broader population.

Roche the primary progression-fbreast cancerreadout, Roche continued to collect overall survival (OS) data. prostate cancertes suggested ipatasertib was dead in the water, with Roche reporting no significant improvement in OS at the second interim analysis last summer. In September, the U.K. cost watchdog said Roche was working toward final OS analysis in mid-2023 but had dropped plans to seek approval.

Roche confirmed the end of ipatasertib on Thursday byRocheing the prostate cancer study among its newly abandoned phase 3 programs. Ipataipatasertib alongside Roche’s previouslyRochelosed termination of the gantenerumab Alzheimer’s disease trial on the list.Roche

Rochepdate also features onipatasertibse termination. Roche has puprostate cancertrial of efmarodocokin alfa in aGVHD from its pipelIpatasertibug candidate, alRocheown as UTTR1147A, is a recombinant fusion pgantenerumabRAlzheimer’s diseasee 2 as a treatment for ulcerative colitis and Crohn’s disease. However, having failed to make the grade in those indications or aGVHD, the asset has landed on the scrapheap.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构